ProMIS Neurosciences Inc.
PMN · XNASCIK 1374339fmd_0Y3KNE4PNN66W5V8D1XHM7N5R9Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2021 to Sep 30, 2026, 22 periods
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Research and development | 5 | 16 | 8 | 11 | 33 |
| Total operating expenses | 8 | 23 | 14 | 17 | 40 |
| Operating income | (8) | (23) | (14) | (17) | (40) |
| Interest expense | 0 | 0 | – | – | – |
| Other non-operating income (expense) | (1) | 5 | 1 | 20 | 0 |
| Income tax expense | – | 0 | 0 | 0 | – |
| Net income | (10) | (18) | (13) | 3 | (40) |
| Net income to common shareholders | 10 | 18 | (13) | 3 | (40) |